TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ACR response proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough threshold for capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eosinophils in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhaled beta 2 agonist consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or dependence
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in near vision visual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per quality-adjusted life year (QALY)
Endpoint domain: Resource use
Primary endpoint: Postoperative myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total color difference delta E
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fluid diet tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Regular diet tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decline in daily functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DPN pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases of HPV 6/11/16/18-related CIN or EGL
Endpoint domain: Mortality/survival
Primary endpoint: Immunogenicity against vaccine-related HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD rating scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney Disease Quality‐of‐Life End‐Stage Renal Disease Symptom domain score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health Utilities Index Mark 2 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: anal incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical examination findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: translabial ultrasonography findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Performance Status (PS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fluoride retention in whole saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride retention in interdental fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride retention in interdental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the triazolam concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentrations of triazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean lash position scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sitting time at work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased overall sense of well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stop-Signal reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective ratings of light-headedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TGF‐β level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Red blood cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increased expression of Th2‐associated CCL22 in CBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Contraceptive Knowledge Inventory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with counseling method
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant contraceptive preference for long‐acting reversible contraceptives (LARCs)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adjusted HbA(1c) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total ARAT score at day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization grades of upper abdominal arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Appearance rate of intrahepatic portal branches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean total BPRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI ratings of global improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the concentration-time curve (AUC) of paritaprevir and dasabuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's behaviour during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validated tobacco abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Wolf Motor Function Test‐Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wolf Motor Function Test‐Functional Ability Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPI-Q score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvements in abnormal bleeding patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: likelihood of speaking up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in subsequent cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total nonspecific systemic resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracardiac hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: adequate occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aneurysm remnant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interobserver agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPI-NH Psychosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in days spent in psychiatric inpatient services
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Satisfaction with psychiatric services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cure rates for hookworm infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Egg reduction rates for hookworm infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Resistance to antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Susceptibility to ceftriaxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduced susceptibility to ciprofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nail Psoriasis Severity Index (NAPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative temperature and humidity values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coronary artery diameter (CADM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of macular drusen >63 μm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: composite of major adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Survival free from severe dependence
Endpoint domain: Mortality/survival
Primary endpoint: grades 3 and 4 leukocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: lnTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lnLF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to diabetes treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral visual field changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event reporting
Endpoint domain: Adverse events/effects
Primary endpoint: serum triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: lipoprotein(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change in symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in peak urinary-flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMJ pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Mouth Opening (MMO) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint sound decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of Vitamin D Insufficiency (VDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea severity
Endpoint domain: Adverse events/effects
Primary endpoint: Use of rescue anti-emetics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: thermal and mechanical antihyperalgesic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attenuated thermal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of internal sphincter relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Preoperative pain and numbness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriuria rate at catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decreased rhinitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication scores significantly decreased
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant decrease in wheal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean FEV1 AUC0‐12 h change from baseline at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean increase in FEV1 at 5 minutes postdose on day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of adverse events related to study therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Length of stay (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal integrity success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: costs of instrumentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DFT energy requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception from shocks
Endpoint domain: Adverse events/effects
Primary endpoint: Deaths from lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: intensity of acute dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Stretched penile length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of men with mean loss of penile length >/= 2 cm
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of Reddy female condom
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erythroid response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CARS stability over 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burst pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urinary morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to place the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to start the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean aortic intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Re-operation for continuous stress urinary incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: Procedural costs
Endpoint domain: Resource use
Primary endpoint: Endothelium-dependent contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inhibition of endothelium-dependent relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total cannulation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Colony-forming units (CFUs) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients receiving all cycles of preoperative chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients proceeding to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or higher surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of headache (hour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UFOV performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: unmet needs for care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean reduction in daily 'off' time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of CD18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in average neuropathic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft failure rates
Endpoint domain: Mortality/survival
Primary endpoint: Mean FFR reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyebrow fullness or thickness and darkness or color
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive performance (verbal memory, delayed recall, attention)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postocclusion peak flow velocity of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for re-treatment of OAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the scheduled treatment period
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean test score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACL-QOL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee flexion and extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IFNalpha activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Disease Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High depression risk (EPDS > or = 10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cough frequency or score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in FEV1 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sustained bronchodilation for 12 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lp-PLA2 mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: delta 4‐androstenedione serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: hirsutism improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborn DNA methylation of specific CpG sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in CIL supports
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Obtaining substantive support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Tangible new resource
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean proteinuria over creatinuria ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Probability of complete or partial remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: onset and duration of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative pain experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average quality of CC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage in target depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of CC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: change in sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in left atrial size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of sunburn
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of IL-6, IL-8, IL-9, and IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CAS response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of diplopia and proptosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of words recalled at HVLT recall 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scores in the Atlantis Delayed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IELT (Intravaginal Ejaculatory Latency Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intercourse satisfaction (International Index of Erectile Function)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean weekly intercourse episodes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: verbal learning and recognition memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: consolidation/retrieval (memory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: design learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes